Digital health advisory case studies
Explore how Galen Growth helps healthcare leaders, investors, insurers, pharmaceutical companies, medical device teams, and public-sector organisations move from fragmented market signals to decision-grade digital health intelligence.
Use cases
Each engagement is powered by HealthTech Alpha and shaped by analyst interpretation so the output is usable in board, strategy, investment, market access, and partnership decisions.
Prioritise geographies, ecosystems, access pathways, and venture categories before committing capital or commercial focus.
Screen, benchmark, and validate ventures before investment, acquisition, partnership, or market access decisions.
Track competitor moves, partnership patterns, product signals, and market positioning across digital health categories.
Assess exposure, duplication, readiness, governance gaps, and evidence strength across digital health portfolios.
Turn fragmented health innovation signals into decision-ready roadmaps for pharma, medtech, insurers, investors, and health systems.
Evaluate reimbursement, adoption, evidence, partnership, and ecosystem constraints that shape commercialisation.
How Galen Growth supports decisions
Across the 2024-2026 portfolio, our work clusters around three recurring decision needs: competitor visibility, market and partner prioritisation, and evidence-based portfolio or diligence decisions.
Galen Growth tracks competitor partnerships, investments, therapeutic priorities and venture signals so leadership teams can identify white space, risk and strategic response options.
Used across global franchise strategy, APAC competitor mapping and biopharma partnership benchmarking.We compare ecosystem maturity, venture depth, patient cohorts, investment activity and partnership readiness to determine which markets and companies deserve focus.
Applied in women’s health roadmaps, APAC insurer strategy, clinical-trial scouting and digital health readiness assessments.We evaluate ventures, partnerships and portfolios against strategic fit, evidence, maturity, compliance, operational readiness and category benchmarks.
Used for non-fluid underwriting, cardiac remote monitoring, GDPR-ready telemonitoring, RWE thesis work and portfolio fitness reviews.Selected work
Filter by client sector, business vertical, or ecosystem to find relevant examples of Galen Growth work.
Biopharma
As part of a full franchise strategy review, a leading pharmaceutical company was looking to evaluate its global portfolio of existing partnerships with Digital Health ventures to confirm…
Read case studyInsurance
A global re-insurer wanted to identify mature ventures across non-fluid underwriting, digital biomarkers, digital therapeutics, genomics and teleconsultation
Read case studyVenture Capital
The Corporate Venture Capital (CVC) arm of a global reinsurance company wanted to, as part of their ongoing due diligence, undertake a global competitive analysis in the genomics…
Read case studyVenture Capital
The Corporate Venture Capital (CVC) arm of a global pharmaceutical company wanted to analyse a specific key APAC market to assess both the macro and micro-environment for Real…
Read case studyMedical Device
A global leading medical device company sought to understand the personal health Digital Health landscape for two priority therapeutic areas in key global ecosystems to identify and evaluate…
Read case studyBiopharma
As part of a full franchise strategy review, a leading pharmaceutical company was looking to evaluate its global portfolio of existing partnerships with Digital Health ventures to confirm…
Read case studyBiopharma
A global biotech wanted to understand the pan-omics (e.g. proteomics) digital health landscape and ecosystems within two key regional ecosystems
Read case studyBiopharma
A global pharmaceutical wanted to shortlist and prioritise ventures which provided a solution with telemonitoring capabilities, that connects patients suffering from heart failure and physicians (cardiologists). Ventures of…
Read case studyBiopharma
A global pharmaceutical wanted to identify and shortlist proven ventures that have developed a specific Digital biomarker scoring algorithm capability
Read case studyInsurance
An APAC focused insurer wanted to analyse other insurers in the region, in order to identify their competitors key areas of focus, and determine a ‘follow’ or differentiation…
Read case studyInsurance
This global Insurer looked to accelerate its Digital Health footprint in Asia, prioritise markets for innovation, and scout for HealthTech ventures that met specific Therapeutic and Category objectives
Read case studyBiopharma
Our client, a leading global biopharma, wanted monitor how biopharma is investing and operating in Digital Health across their value chain, to better support its own Digital Health…
Read case studyInsurance
A Regional insurance company wanted to identify innovative solutions and business models within the OMICS realm that are tackling Oncology and Wellness.
Read case studyMedical Device
Our client, one of the major global medical device companies, wanted to identify digital health solutions across five markets: USA, France, Germany, UK and Italy. Their specific focus…
Read case studyBiopharma
A large pharmaceutical player sought oncology ventures that could offer advice, patient cohorts, or clinical trials capabilities, in LATAM, Middle East & Asia
Read case studyBiopharma
A global pharma company specialized in women’s health wanted to analyse its priority markets in order to build the future roadmap of innovative solutions for women, starting from…
Read case studyBiopharma
How should we track competitor activity across obesity, diabetes and cardiovascular disease to support global strategic decisions?
Read case studyBiopharma
Which priority markets and venture partners should anchor our future women’s health innovation roadmap, starting with telemedicine?
Read case studyInsurance
Which OMICS-led ventures tackling oncology and wellness are mature enough to partner with an enterprise insurer?
Read case studyBiopharma
Where are competitors investing and partnering in Digital Health, and what should that mean for our own portfolio strategy?
Read case studyBiopharma
Which APAC markets should we prioritise for Digital Health investment, and where is our franchise readiness strongest?
Read case studyBiopharma
Which oncology ventures in emerging markets can offer advice, patient cohorts or clinical trial capability at scale?
Read case studyMedical Device
Which cardiac remote monitoring ventures are mature enough to support personalised patient care across our priority markets?
Read case studyInsurance
Which ventures across digital biomarkers, DTx, genomics and teleconsultation are mature enough to enable non-fluid underwriting?
Read case studyInsurance
How does our preferred venture partner compare against credible alternatives in the same market and therapeutic focus?
Read case studyInsurance
Which APAC markets, therapeutic areas and Digital Health categories should we prioritise to accelerate regional growth?
Read case studyInsurance
Where are our regional competitors investing in Digital Health, and should we follow or differentiate?
Read case studyBiopharma
Which ventures have a proven, differentiated digital biomarker scoring algorithm in oncology?
Read case studyBiopharma
Which telemonitoring ventures can credibly connect heart-failure patients with cardiologists and meet our eight enterprise criteria?
Read case studyBiopharma
Where is pan-omics innovation concentrated across Europe and Asia, and which ventures warrant deeper engagement?
Read case studyMedical Device
Which personal-health ventures are the optimal fit for our two priority therapeutic areas across the major global ecosystems?
Read case studyBiopharma
Is our existing Digital Health portfolio fit for purpose against our updated franchise strategy?
Read case studyVenture Capital
Is real-world evidence in China a defensible thesis, and which ventures are emerging as category leaders?
Read case studyBiopharma
Which APAC Digital Health ventures can help us drive HPV awareness, cervical cancer action and immuno-oncology innovation?
Read case studyPublic Sector
How does Singapore’s Digital Health ecosystem compare globally, and where should national policy and investment focus?
Read case studyNo case studies match this filter yet.
Decision-grade intelligence
Galen Growth combines HealthTech Alpha data with expert analysis to support digital health market expansion, competitive intelligence, market access strategy, portfolio risk stratification, partner identification, and transaction due diligence.
Our work is designed for teams that need traceable intelligence, not generic research: pharmaceutical innovation teams, medical device strategy groups, insurers, health systems, investors, corporate venture teams, and public-sector health innovation leaders.
